Pfizer discontinues hemophilia treatment Beqvez, emptying its gene therapy portfolio
By Angus Liu,
Fierce Pharma
| 02. 21. 2025
Pfizer is pulling further away from the gene therapy field with its decision to discontinue hemophilia product Beqvez.
The New York pharma is ending global development and commercialization of Beqvez less than a year after an FDA approval for the gene therapy to treat hemophilia B. The one-time treatment carried a list price of $3.5 million per person.
Several reasons led to the discontinuation, including limited interest from patients and doctors toward hemophilia gene therapies to date, a Pfizer spokesperson told Fierce Pharma in a statement.
No patients seem to have received commercial Beqvez since its FDA nod in April 2024. The Pfizer spokesperson said the company will communicate the news to patients and providers that are in the treatment qualification process, adding that the company remains committed to supporting those who received the med in any clinical trial.
Following Beqvez’s exit from the market, Pfizer has no commercial or clinical-stage gene therapies left in the works, according to its website. The spokesperson confirmed that the company doesn’t have any active gene therapy programs at the moment.
Step by step...
Related Articles
President Trump scored a bunch of generally favorable mainstream headlines recently by announcing that he was ordering expanded access to in vitro fertilization (IVF). He had announced in October that he was “the father of IVF” although he also said he had only just learned what it was from Senator Katie Britt (R-AL), who explained it to him over the phone. “And within about two minutes, I understood it.”
The executive order, as reporter Susan Rinkunas wryly noted at...
By Staff, The Economist | 02.21.2025
One of the greatest scandals in modern science began with a late-2010s advertisement for HIV-positive couples looking to have children through in-vitro fertilisation (IVF). The ad had been put out by a scientist named He Jiankui, a biologist then at...
By Oriol Güell, El País | 02.17.2025
A “small strand of blood in the poop.” This was the first sign, initially viewed as unimportant, that put Jesús Lunar and Cristina López on the trail that something was happening with their son’s health. Javier had been born on...
By Bertha Coombs, CNBC | 02.18.2025
Starting in his early teens, Deshawn “DJ” Chow wasn’t sure he’d ever be able to live a normal life. Crushing pain episodes brought on by his sickle cell disease were getting progressively worse.
“It’s just been hard skipping school...
